Ascendis Pharma A/S (NASDAQ:ASND) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Ascendis Pharma A/S (NASDAQ:ASND) have earned a consensus recommendation of “Moderate Buy” from the fourteen brokerages that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and thirteen have issued a buy recommendation on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $204.64.

Several analysts have commented on ASND shares. UBS Group started coverage on shares of Ascendis Pharma A/S in a research report on Tuesday, January 7th. They set a “buy” rating and a $196.00 target price for the company. JPMorgan Chase & Co. upped their price objective on Ascendis Pharma A/S from $168.00 to $200.00 and gave the company an “overweight” rating in a report on Tuesday, March 18th. Morgan Stanley set a $180.00 target price on Ascendis Pharma A/S in a report on Tuesday, February 18th. Cantor Fitzgerald boosted their target price on Ascendis Pharma A/S from $170.00 to $200.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 25th. Finally, The Goldman Sachs Group increased their price target on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the company a “buy” rating in a research report on Thursday, February 13th.

Institutional Investors Weigh In On Ascendis Pharma A/S

Several institutional investors have recently bought and sold shares of the company. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Ascendis Pharma A/S in the fourth quarter worth $28,000. Wilmington Savings Fund Society FSB acquired a new position in Ascendis Pharma A/S during the third quarter worth $30,000. Jones Financial Companies Lllp raised its position in Ascendis Pharma A/S by 394.0% during the fourth quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company’s stock worth $34,000 after acquiring an additional 197 shares in the last quarter. Blue Trust Inc. increased its stake in shares of Ascendis Pharma A/S by 415.2% during the 4th quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company’s stock worth $56,000 after purchasing an additional 328 shares during the last quarter. Finally, GAMMA Investing LLC raised its stake in Ascendis Pharma A/S by 58.0% in the 4th quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company’s stock valued at $80,000 after acquiring an additional 214 shares during the period.

Ascendis Pharma A/S Stock Performance

Shares of ASND opened at $167.99 on Tuesday. The business’s fifty day moving average price is $142.05 and its two-hundred day moving average price is $136.15. The firm has a market capitalization of $10.20 billion, a price-to-earnings ratio of -23.66 and a beta of 0.62. Ascendis Pharma A/S has a 52 week low of $111.09 and a 52 week high of $169.37.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.68) EPS for the quarter, topping analysts’ consensus estimates of ($1.32) by $0.64. As a group, research analysts forecast that Ascendis Pharma A/S will post -4.34 EPS for the current year.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.